There are 2137 resources available
1924P - Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)
Presenter: Carlos López
Session: E-Poster Display
Resources:
Abstract
1925P - DNA methylation signature for prediction of metastasis and response to multikinase inhibitors of differentiated thyroid carcinoma (DTC)
Presenter: Jorge Hernando
Session: E-Poster Display
Resources:
Abstract
1926P - PD-L1 expression in medullary thyroid carcinoma and its relevance with clinicopathological findings
Presenter: Yasemin Kemal
Session: E-Poster Display
Resources:
Abstract
1927TiP - LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC)
Presenter: Jorge Hernando
Session: E-Poster Display
Resources:
Abstract
1934P - Research and contextual inquiry on information and communication technologies point of care systems for cancer follow-up
Presenter: Victor Vicente Blanco
Session: E-Poster Display
Resources:
Abstract
1935P - AI-driven big data analytics for effective response of cancer therapy (AIBERT drug discovery and development platform)
Presenter: Xinxin Peng
Session: E-Poster Display
Resources:
Abstract
1936P - Mis-selection of non-malignant lesions as target lesions: Misclassification of RECIST 1.1 and early termination of promising drugs
Presenter: Antoine Iannessi
Session: E-Poster Display
Resources:
Abstract
1937P - ERN GENTURIS guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes
Presenter: Rita Magenheim
Session: E-Poster Display
Resources:
Abstract
1938P - Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trial
Presenter: Armin Gerger
Session: E-Poster Display
Resources:
Abstract
1939P - Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)
Presenter: Laura Bonanno
Session: E-Poster Display
Resources:
Abstract